• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

综述文章:肠道疾病治疗中的靶向药物递送

Review article: Targeted drug delivery in treatment of intestinal diseases.

作者信息

Wikberg M, Ulmius J, Ragnarsson G

机构信息

Pharmaceutical and Analytical Research and Development, Astra Draco AB, Lund, Sweden.

出版信息

Aliment Pharmacol Ther. 1997 Dec;11 Suppl 3:109-15. doi: 10.1111/j.1365-2036.1997.tb00815.x.

DOI:10.1111/j.1365-2036.1997.tb00815.x
PMID:9467985
Abstract

Topical therapy within the treatment of intestinal diseases presents realistic formulation challenges for targeted drug delivery. Some relevant oral formulation concepts are reviewed. The basic principles employed are based mainly on differences in pH and metabolic activity between the different parts of the gastrointestinal tract. A successful example of targeted drug delivery within the treatment of Crohn's disease is presented. Topical therapy for the treatment of ulcerative colitis is also discussed. Physiological variations and influence of the disease and disease status present major challenges when deciding upon a suitable formulation principle.

摘要

肠道疾病治疗中的局部治疗在靶向给药方面面临着实际的制剂挑战。本文综述了一些相关的口服制剂概念。所采用的基本原则主要基于胃肠道不同部位的pH值和代谢活性差异。文中介绍了克罗恩病治疗中靶向给药的一个成功实例。还讨论了溃疡性结肠炎治疗的局部疗法。在确定合适的制剂原则时,生理差异以及疾病和病情的影响带来了重大挑战。

相似文献

1
Review article: Targeted drug delivery in treatment of intestinal diseases.综述文章:肠道疾病治疗中的靶向药物递送
Aliment Pharmacol Ther. 1997 Dec;11 Suppl 3:109-15. doi: 10.1111/j.1365-2036.1997.tb00815.x.
2
Reviewing the therapeutic role of budesonide in Crohn's disease.回顾布地奈德在克罗恩病中的治疗作用。
Gastroenterol Hepatol. 2018 Aug-Sep;41(7):458-471. doi: 10.1016/j.gastrohep.2018.05.013. Epub 2018 Jul 12.
3
[Topical steroids in chronic inflammatory bowel diseases].[局部类固醇药物在慢性炎症性肠病中的应用]
Internist (Berl). 1997 Dec;38(12):1154-9. doi: 10.1007/s001080050127.
4
[Chronic inflammatory bowel diseases. Update on evidence-based therapy].[慢性炎症性肠病。循证治疗的最新进展]
MMW Fortschr Med. 2005 Apr 28;147(17):58-9.
5
A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.布地奈德多矩阵片治疗溃疡性结肠炎的安全性评估。
Expert Opin Drug Saf. 2018 Apr;17(4):437-444. doi: 10.1080/14740338.2018.1442432. Epub 2018 Feb 23.
6
The role of Budesonide-MMX in active ulcerative colitis.布地奈德多矩阵片在活动性溃疡性结肠炎中的作用。
Expert Rev Gastroenterol Hepatol. 2014 Mar;8(3):215-22. doi: 10.1586/17474124.2014.887437. Epub 2014 Feb 6.
7
Budesonide modified-release capsules.布地奈德缓释胶囊
Rev Gastroenterol Disord. 2001;1(3):147-55.
8
Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy.
Aliment Pharmacol Ther. 1997 Dec;11 Suppl 3:98-107; discussion 107-8. doi: 10.1111/j.1365-2036.1997.tb00814.x.
9
Budesonide for the treatment of ulcerative colitis.布地奈德用于治疗溃疡性结肠炎。
Expert Opin Pharmacother. 2016 Aug;17(11):1549-59. doi: 10.1080/14656566.2016.1183648. Epub 2016 Jun 16.
10
Oral budesonide approved for active Crohn's disease.口服布地奈德被批准用于治疗活动性克罗恩病。
Am J Health Syst Pharm. 2001 Dec 1;58(23):2229. doi: 10.1093/ajhp/58.23.2229.

引用本文的文献

1
Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn's Disease Patients through PBPK Modeling.通过生理药代动力学(PBPK)模型理解布地奈德在健康人和克罗恩病患者中的体外溶出度、局部肠道和全身生物等效性之间的差异。
Pharmaceutics. 2023 Aug 30;15(9):2237. doi: 10.3390/pharmaceutics15092237.
2
Predicting and Understanding the Human Microbiome's Impact on Pharmacology.预测和理解人类微生物组对药理学的影响。
Trends Pharmacol Sci. 2019 Jul;40(7):495-505. doi: 10.1016/j.tips.2019.04.014. Epub 2019 Jun 3.
3
Organelle targeting: third level of drug targeting.
细胞器靶向:药物靶向的第三个层次。
Drug Des Devel Ther. 2013 Jul 17;7:585-99. doi: 10.2147/DDDT.S45614. Print 2013.
4
Inflammatory bowel disease: perioperative pharmacological considerations.炎症性肠病:围手术期药理学考虑。
Mayo Clin Proc. 2011 Aug;86(8):748-57. doi: 10.4065/mcp.2011.0074.
5
Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.布地奈德(Entocort EC)胶囊用于克罗恩病的药代动力学
Clin Pharmacokinet. 2004;43(12):803-21. doi: 10.2165/00003088-200443120-00003.